803700-29-0

Usage

Uses

Used in Pharmaceutical Research and Development:
3-(3-fluoro-5-nitrophenoxy)pyridine is used as a building block or intermediate for the synthesis of pharmaceuticals. Its unique structure and functional groups make it a valuable component in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Research and Development:
In the agrochemical industry, 3-(3-fluoro-5-nitrophenoxy)pyridine is employed as a precursor in the synthesis of various agrochemicals. Its properties can contribute to the creation of new compounds with pesticidal or herbicidal activities, enhancing crop protection and yield.
Used in Materials Science:
3-(3-fluoro-5-nitrophenoxy)pyridine may have potential applications in materials science due to its structural and chemical characteristics. It could be incorporated into the development of new materials with specific properties, such as improved stability or reactivity.
Used in Organic Electronics:
3-(3-fluoro-5-nitrophenoxy)pyridine may also find use in the field of organic electronics, where its electronic properties could be harnessed for applications in organic light-emitting diodes (OLEDs), organic photovoltaics, or other electronic devices.
Used in Medicinal Chemistry Research:
Due to its potential biological activities, 3-(3-fluoro-5-nitrophenoxy)pyridine is a subject of interest for medicinal chemistry research. Scientists may explore its interactions with biological targets, such as enzymes or receptors, to understand its therapeutic potential and develop new drugs based on its structure.

Upstream product

• 109-00-2 3-HYDROXYPYRIDINE 
• 2265-94-3 1,3-difluoro-5-nitrobenzene 

Downstream Products

• 1245607-47-9 N-(3-fluoro-5-(pyridin-3-yloxy)phenyl)-2-(hydroxymethyl)benzenesulfonamide 
• 1245607-30-0 2-(3-fluoro-5-(pyridin-3-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide 
• 1245607-31-1 2-(3-fluoro-5-(pyridin-3-yloxy)phenyl)isoindoline-1,3-dione 
• 1245607-46-8 methyl 2-(N-(3-fluoro-5-(pyridin-3-yloxy)phenyl)sulfamoyl)benzoate 
• 791644-59-2 3-fluoro-5-(pyridin-3-yloxy)aniline 

Relevant academic research and scientific papers

Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity

The free fatty acid receptor 4 (FFA4 or GPR120) has appeared as an interesting potential target for the treatment of metabolic disorders. At present, most FFA4 ligands are carboxylic acids that are assumed to mimic the endogenous long-chain fatty acid agonists. Here, we report preliminary structure-activity relationship studies of a previously disclosed nonacidic sulfonamide FFA4 agonist. Mutagenesis studies indicate that the compounds are orthosteric agonists despite the absence of a carboxylate function. The preferred compounds showed full agonist activity on FFA4 and complete selectivity over FFA1, although a significant fraction of these noncarboxylic acids also showed partial antagonistic activity on FFA1. Studies in normal and diet-induced obese (DIO) mice with the preferred compound 34 showed improved glucose tolerance after oral dosing in an oral glucose tolerance test. Chronic dosing of 34 in DIO mice resulted in significantly increased insulin sensitivity and a moderate but significant reduction in bodyweight, effects that were also present in mice lacking FFA1 but absent in mice lacking FFA4.

NOVEL ISOINDOLIN-1-ONE DERIVATIVE

The present invention relates to a compound represented by formula (I): (wherein R1, R2, R3 and R4 each independently represent a hydrogen or halogen atom; R5 and R6 each independently represent a hydrogen atom or lower alkyl or together represent oxo; X represents C(O) or the like; Y represents an oxygen atom or the like; Z represents a hydrogen atom or the like; R represents 5- or 6-membered heteroaryl having 1-3 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms, contained within a ring, or the like) or to a pharmaceutically acceptable salt thereof.

Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin

We report the design, synthesis, and optimization of the first, selective activators of cardiac myosin. Starting with a poorly soluble, nitro-aromatic hit compound (1), potent, selective, and soluble myosin activators were designed culminating in the discovery of omecamtiv mecarbil (24). Compound 24 is currently in clinical trials for the treatment of systolic heart failure.

2-{2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: A highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist

Structure-activity relationship studies on 3-(5-pyridin-2-yl-2H-tetrazol-2- yl)benzonitrile 2 led to the discovery of 2-{2-[3-(pyridin-3-yloxy)phenyl]-2H- tetrazol-5-yl}pyridine (10)-a highly potent and selective mGlu5 receptor antagonist with good brain penetration and in vivo receptor occupancy in rat and cross-species oral bioavailability. Structure-activity relationship studies on 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 2 led to the discovery of 2-{2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine (10)-a highly potent and selective mGlu5 receptor antagonist with good brain penetration and in vivo receptor occupancy in rat and cross-species oral bioavailability.